# A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

> **NCT06190886** · PHASE1 · RECRUITING · sponsor: **Proviva Therapeutics, Inc.** · enrollment: 26 (estimated)

## Conditions studied

- Advanced Cancer
- Solid Tumor
- Metastatic Cancer

## Interventions

- **DRUG:** PTX-912

## Key facts

- **NCT ID:** NCT06190886
- **Lead sponsor:** Proviva Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2026-05-14
- **Final completion:** 2026-07-24
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06190886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06190886, "A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT06190886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*